Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

While effective in preventing stroke in patients with atrial fibrillation (AF), warfarin is limited by a narrow therapeutic profile, a need for lifelong coagulation monitoring, and multiple drug and diet interactions.

Related collections

Author and article information

Journal

Title: JAMA

Abbreviated Title: JAMA

Publisher: American Medical Association (AMA)

ISSN (Print): 0098-7484

Publication date Created: November 19 2014

Publication date (Print): November 19 2014

Volume: 312

Issue: 19

Page: 1988

Affiliations

[1 ]Mount Sinai School of Medicine, New York City, New York2St John’s Health Center, Santa Monica, California3Homolka Hospital, Prague, Czech Republic

[2 ]Cardiovascular Center Frankfurt, Sankt Katharinen, Frankfurt, Germany

[3 ]Mount Sinai School of Medicine, New York City, New York

[4 ]St John’s Health Center, Santa Monica, California

[5 ]Foundation for Cardiovascular Medicine, La Jolla, California

[6 ]Homolka Hospital, Prague, Czech Republic

[7 ]St Luke’s Hospital, Kansas City, Missouri

[8 ]Intermountain Medical Center, Murray, Utah

[9 ]Cedars Sinai Medical Center, Los Angeles, California

[10 ]Arizona Heart Rhythm Center, Scottsdale

[11 ]Boston Scientific, St Paul, Minnesota

[12 ]Mayo Clinic College of Medicine, Rochester, Minnesota

Article

DOI: 10.1001/jama.2014.15192

PubMed ID: 25399274

SO-VID: 4db5c4f0-6812-4da2-a8fa-bcc944c4429e

History

Data availability:

Comments

Comment on this article

scite_

Cited by 217

See all cited by

- Version 1

Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation : A Randomized Clinical Trial

Read this article at